Compare Tidewater Inc (TDW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs GeneDx Holdings Corp — how do they compare? Tidewater Inc trades at $84.9 (market cap $4.21B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Tidewater Inc is far larger — about 2.1× GeneDx Holdings Corp's market cap, and Tidewater Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and GeneDx Holdings Corp for 19 Days on average.
| TDW | WGS | |
|---|---|---|
Market Cap | $4.21B | $2.02B |
Volume | 590,005 | 734,640 |
Sector | Energy | Health |
52-Week High | $100.61 | $167.51 |
52-Week Low | $47.29 | $34.51 |
Typical Hold Time | 26 Days | 19 Days |
Enterprise Value | $4.25B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $85.42, up 2.42% with bullish technical indicators and strong institutional interest. The company maintains solid profitability with 18.34% net margin and 19.49% ROE, though recent quarterly earnings have missed expectations. Recent acquisition of Wilson Sons Ultratug expands offshore services capabilities, while BlackRock's $503 million investment signals confidence in long-term prospects.
TDW presents a mixed outlook with analyst consensus target of $105.50 offering 23% upside potential, but faces execution risks from recent earnings misses and Middle East operational costs. The stock's valuation at 17.18 P/E appears reasonable given growth prospects, though investors should monitor quarterly performance consistency and integration of recent acquisitions.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
